Nerve growth factor improves the muscle regeneration capacity of muscle stem cells in dystrophic muscle

Human Gene Therapy

Volumn 17, Issue 2, 2006, Pages 180-192

  Lavasani, Mitra ^a,b   Lu, Aiping ^b   Peng, Hairong ^b   Cummins, James ^b   Huard, Johnny ^a,b,c,d  

^a University of Pittsburgh   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; GROWTH FACTOR; NERVE GROWTH FACTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC ENGINEERING; MALE; MARKER GENE; MOUSE; MULTIPOTENT STEM CELL; MUSCLE REGENERATION; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NONHUMAN; POSTNATAL DEVELOPMENT; PROGRESSIVE MUSCULAR ATROPHY; SATELLITE CELL; STEM CELL GENE THERAPY;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CELLS, CULTURED; FEMALE; GENE THERAPY; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NERVE GROWTH FACTOR; PLURIPOTENT STEM CELLS; REGENERATION;

ANIMALIA;

EID: 32944470059     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.180     Document Type: Article

References (63)

1. ACOSTA, C.G., FABREGA, A.R., MASCO, D.H., and LOPEZ, H.S. (2001). A sensory neuron subpopulation with unique sequential survival dependence on nerve growth factor and basic fibroblast growth factor during development. J. Neurosci. 21, 8873-8885.
2. ALLEN, J.B., MANTHEY, C.L., HAND, A.R., OHURA, K., ELLINGSWORTH, L., and WAHL, S.M. (1990). Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β. J. Exp. Med. 171, 231-247.
3. ALMAN, B.A. (2005). Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. J. Pediatr. Orthop. 25, 554-556.
4. ANDERSON, J.E., LIU, L., and KARDAMI, E. (1991). Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles. Dev. Biol. 147, 96-109.
5. ANDERSON, W.F. (1992). Human gene therapy. Science 256, 808-813.
6. ARAHATA, K., ISHIURA, S., ISHIGURO, T., TSUKAHARA, T., SUHARA, Y., EGUCHI, C., ISHIHARA, T., NONAKA, I., OZAWA, E., and SUGITA, H. (1988). Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 333, 861-863.
7. BACH, J.R., CAMPAGNOLO, D.I., and HOEMAN, S. (1991). Life satisfaction of individuals with Duchenne muscular dystrophy using long-term mechanical ventilatory support. Am. J. Phys. Med. Rehabil. 70, 129-135.
8. BARON, P., SCARPINI, E., MEOLA, G., SANTILLI, I., CONTI, G., PLEASURE, D., and SCARLATO, G. (1994). Expression of the low-affinity NGF receptor during human muscle development, regeneration, and in tissue culture. Muscle Nerve 17, 276-284.
9. BIGGAR, W.D., POLITANO, L., HARRIS, V.A., PASSAMANO, L., VAJSAR, J., ALMAN, B., PALLADINO, A., COMI, L.I., and NIGRO, G. (2004). Deflazacort in Duchenne muscular dystrophy: A comparison of two different protocols. Neuromuscul. Disord. 14, 476-482.
10. BONILLA, E., SAMITT, C.E., MIRANDA, A.F., HAYS, A.P., SALVIATI, G., DIMAURO, S., KUNKEL, L.M., HOFFMAN, E.P., and ROWLAND, L.P. (1988). Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. Cell 54, 447-452.
11. BUSHBY, K., MUNTONI, F., URTIZBEREA, A., HUGHES, R., and GRIGGS, R. (2004). Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy: Defining the gold standards of management in the use of corticosteroids. April 2-4, 2004, Naarden, The Netherlands. Neuromuscul. Disord. 14, 526-534.
12. CAMPBELL, C., and JACOB, P. (2003). Deflazacort for the treatment of Duchenne dystrophy: A systematic review. BMC Neurol. 3, 7.
13. CAPSONI, S., RUBERTI, F., DI DANIEL, E., and CATTANEO, A. (2000). Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. J. Neurosci. Res. 59, 553-560.
14. CLARKE, M.S., KHAKEE, R., and MCNEIL, P.L. (1993). Loss of cytoplasmic basic fibroblast growth factor from physiologically wounded myofibers of normal and dystrophic muscle. J. Cell Sci. 106, 121-133.
15. DEASY, B.M., QU-PETERSEN, Z., GREENBERGER, J.S., and HUARD, J. (2002). Mechanisms of muscle stem cell expansion with cytokines. Stem Cells 20, 50-60.
16. DIMARIO, J., BUFFINGER, N., YAMADA, S., and STROHMAN, R.C. (1989). Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 244, 688-690.
17. DUCHENNE, G.B. (1868). Researches sur la paralysie musculaire pseudo-hyperophique ou paralysie myo-sclerotique. Arch. Gen. Med. 11, 179, 305, 421, 552.
18. EAGLE, M. (2002). Report on the muscular dystrophy campaign workshop: Exercise in neuromuscular diseases Newcastle, January 2002. Neuromuscul. Disord. 12, 975-983.
19. EVANS, C.H., and ROBBINS, P.D. (1994). The interleukin-1 receptor antagonist and its delivery by gene transfer. Receptor 4, 9-15.
20. FLORINI, J.R., EWTON, D.Z., and MAGRI, K.A. (1991). Hormones, growth factors, and myogenic differentiation. Annu. Rev. Physiol. 53, 201-216.
21. GOROSPE, J.R., and HOFFMAN, E.P. (1992). Duchenne muscular dystrophy. Curr. Opin. Rheumatol. 4, 794-800.
22. GROUNDS, M.D. (1991). Towards understanding skeletal muscle regeneration. Pathol. Res. Pract. 187, 1-22.
23. HARPER, C.M., AMBLER, G., and EDGE, G. (2004). The prognostic value of pre-operative predicted forced vital capacity in corrective spinal surgery for Duchenne's muscular dystrophy. Anaesthesia 59, 1160-1162.
24. HOFFMAN, E.P., BROWN, R.H., Jr., and KUNKEL, L.M. (1987a). Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
25. HOFFMAN, E.P., MONACO, A.P., FEENER, C.C., and KUNKEL, L.M. (1987b). Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 238, 347-350.
26. HUTTER, O.F., BURTON, F.L., and BOVELL, D.L. (1991). Mechanical properties of normal and mdx mouse sarcolemma: bearing on function of dystrophin. J. Muscle Res. Cell Motil. 12, 585-589.
27. JANKOWSKI, R.J., DEASY, B.M., CAO, B., GATES, C., and HUARD, J. (2002). The role of CD34 expression and cellular fusion in the regeneration capacity of myogenic progenitor cells. J. Cell Sci. 115, 4361-4374.
28. KASEMKIJWATTANA, C., MENETREY, J., BOSCH, P., SOMOGYI, G., MORELAND, M.S., FU, F.H., BURANAPANITKIT, B., WATKINS, S.S., and HUARD, J. (2000). Use of growth factors to improve muscle healing after strain injury. Clin. Orthop. 370, 272-285.
29. KINOSHITA, I., VILQUIN, J.T., GUERETTE, B., ASSELIN, I., ROY, R., and TREMBLAY, J.P. (1994). Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17, 1407-1415.
30. KUSHIMA, Y., NISHIO, C., NONOMURA, T., and HATANAKA, H. (1992). Effects of nerve growth factor and basic fibroblast growth factor on survival of cultured septal cholinergic neurons from adult rats. Brain Res. 598, 264-270.
31. LU, Q.L., MANN, C.J., LOU, F., BOU-GHARIOS, G., MORRIS, G.E., XUE, S.A., FLETCHER, S., PARTRIDGE, T.A., and WILTON, S.D. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014.
32. LYNCH, G.S. (2001). Therapies for improving muscle function in neuromuscular disorders. Exerc. Sport Sci. Rev. 29, 141-148.
33. LYNCH, G.S., RAFAEL, J.A., CHAMBERLAIN, J.S., and FAULKNER, J.A. (2000). Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. Am. J. Physiol. Cell Physiol. 279, C1290-C1294.
34. MANZUR, A.Y., KUNTZER, T., PIKE, M., and SWAN, A. (2004). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 2, CD003725.
35. MCCALLISTER, W.V., TANG, P., SMITH, J., and TRUMBLE, T.E. (2001). Axonal regeneration stimulated by the combination of nerve growth factor and ciliary neurotrophic factor in an end-to-side model. J. Hand Surg. Am. 26, 478-488.
36. MENETREY, J., KASEMKIJWATTANA, C., DAY, C.S., BOSCH, P., VOGT, M., FU, F.H., MORELAND, M.S., and HUARD, J. (2000). Growth factors improve muscle healing in vivo. J. Bone Joint Surg. Br. 82, 131-137.
37. MENKE, A., and JOCKUSCH, H. (1991). Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 349, 69-71.
38. MILLER, A.R., SKOTZKO, M.J., RHOADES, K., BELLDEGRUN, A.S., TSO, C.L., KABOO, R., MCBRIDE, W.H., JACOBS, E., KOHN, D.B., and MOEN, R. (1992). Simultaneous use of two retroviral vectors in human gene marking trials: Feasibility and potential applications. Hum. Gene Ther. 3, 619-624.
39. MISKE, L.J., HICKEY, E.M., KOLB, S.M., WEINER, D.J., and PANITCH, H.B. (2004). Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. Chest 125, 1406-1412.
40. OU, J.Y., CHAMBERS, J., and WHEELER, E.F. (1999). Myoblasts differentiation is accompanied by expression of the NGF receptors: Effects of NGF on the proliferation and differentiation of myoblasts. In: Proceedings of the 29th Annual Meeting of the Society for Neuroscience. Abstract 94.15.
41. PASTORET, C., and SEBILLE, A. (1993). Further aspects of muscular dystrophy in mdx mice. Neuromuscul. Disord. 3, 471-475.
42. PASTORET, C., and SEBILLE, A. (1995). mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129, 97-105.
43. PENG, H., WRIGHT, V., USAS, A., GEARHART, B., SHEN, H.C., CUMMINS, J., and HUARD, J. (2002). Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Invest. 110, 751-759.
44. PETROF, B.J., STEDMAN, H.H., SHRAGER, J.B., EBY, J., SWEENEY, H.L., and KELLY, A.M. (1993). Adaptations in myosin heavy chain expression and contractile function in dystrophic mouse diaphragm. Am. J. Physiol. 265, C834-C841.
45. QU-PETERSEN, Z., DEASY, B., JANKOWSKI, R., IKEZAWA, M., CUMMINS, J., PRUCHNIC, R., MYTINGER, J., CAO, B., GATES, C., WERNIG, A., and HUARD, J. (2002). Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J. Cell Biol. 157, 851-864.
46. REDDYPALLI, S., ROLL, K., LEE, H.K., LUNDELL, M., BAREA-RODRIGUEZ, E., and WHEELER, E.F. (2005). p75NTR-mediated signaling promotes the survival of myoblasts and influences muscle strength. J. Cell. Physiol. 204, 819-829.
47. RENDE, M. (1998). Nerve growth factor (NGF) stimulates myoblast fusion into myotubes in a rat myogenic cell line (L6): A novel autocrine role for NGF in muscle development. In: Proceedings of the 28th Annual Meeting of Society for Neuroscience. Abstract 801.10.
48. RENDE, M., BRIZI, E., CONNER, J., TREVES, S., CENSIER, K., PROVENZANO, C., TAGLIALATELA, G., SANNA, P.P., and DONATO, R. (2000). Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA. Int. J. Dev. Neurosci. 18, 869-885.
49. ROBBINS, P.D., and GHIVIZZANI, S.C. (1998). Viral vectors for gene therapy. Pharmacol. Ther. 80, 35-47.
50. RUBERTI, F., CAPSONI, S., COMPARINI, A., DI DANIEL, E., FRANZOT, J., GONFLONI, S., ROSSI, G., BERARDI, N., and CATTANEO, A. (2000). Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 20, 2589-2601.
51. SALVATORI, G., FERRARI, G., MEZZOGIORNO, A., SERVIDEI, S., COLETTA, M., TONALI, P., GIAVAZZI, R., COSSU, G., and MAVILIO, F. (1993). Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. Hum. Gene Ther. 4, 713-723.
52. SHERLEY, J.L., STADLER, P.B., and STADLER, J.S. (1995). A quantitative method for the analysis of mammalian cell proliferation in culture in terms of dividing and non-dividing cells. Cell Prolif. 28, 137-144.
53. SHITAKA, Y., and SAITO, H. (1994). The effect of basic fibroblast growth factor (bFGF) and nerve growth factor (NGF) on the survival of septal neurons transplanted into the third ventricle in rats. Jpn. J. Pharmacol. 64, 27-33.
54. SMITH, P.E., COAKLEY, J.H., and EDWARDS, R.H. (1988). Respiratory muscle training in Duchenne muscular dystrophy. Muscle Nerve 11, 784-785.
55. STEDMAN, H.H., SWEENEY, H.L., SHRAGER, J.B., MAGUIRE, H.C., PANETTIERI, R.A., PETROF, B., NARUSAWA, M., LEFEROVICH, J.M., SLADKY, J.T., and KELLY, A.M. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
56. TOTI, P., VILLANOVA, M., VATTI, R., SCHUERFELD, K., STUMPO, M., BARBAGLI, L., MALANDRINI, A., and COSTANTINI, M. (2003). Nerve growth factor expression in human dystrophic muscles. Muscle Nerve 27, 370-373.
57. TRIPPEL, S.B. (1997). Growth factors as therapeutic agents. Instr. Course Lect. 46, 473-476.
58. WATKINS, S.C., HOFFMAN, E.P., SLAYTER, H.S., and KUNKEL, L.M. (1988). Immunoelectron microscopic localization of dystrophin in myofibres. Nature 333, 863-866.
59. WEISS, A., and SCHLESSINGER, J. (1998). Switching signals on or off by receptor dimerization. Cell 94, 277-280.
60. WHEELER, E.F., GONG, H., GRIMES, R., BENOIT, D., and VAZQUEZ, L. (1998). p75NTR and Trk receptors are expressed in reciprocal patterns in a wide variety of non-neural tissues during rat embryonic development, indicating independent receptor functions. J. Comp. Neurol. 391, 407-428.
61. WHITE, T.P., and ESSER, K.A. (1989). Satellite cell and growth factor involvement in skeletal muscle growth. Med. Sci. Sports Exerc. 21, S158-S163.
62. YILMAZ, O., KARADUMAN, A., and TOPALOGLU, H. (2004). Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur. J. Neurol. 11, 541-544.
63. ZHAO, J., YOSHIOKA, K., MIIKE, T., KAGESHITA, T., and ARAO, T. (1991). Nerve growth factor receptor immunoreactivity on the tunica adventitia of intramuscular blood vessels in childhood muscular dystrophies. Neuromuscul. Disord. 1, 135-141.